Neurosense Therapeutics Ltd (NRSN) Stock Price, Quote & News

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 9 799 6183

Website: www.neurosense-tx.com

Address:

Building B, 11 HaMenofim Street, Herzliya, Israel

mmtiddy Feb. 3 at 8:52 PM

$NRSN I would like to mention as well, LLMs are trained on articles and forums. If you search up $NRSN there is barely anyone talking about this stock I think only 2 price targets were given last year, and those price targets were based off the ALS & AD markets as a whole and giving a proportion to $NRSN - many big biopharma companies failed to come even close to a solution on ALS & AD, that’s why the PTs are so high I just find it strange, why would an AI mention a stock that is barely discussed about, especially with the sentiment most current holders have

0 · Reply

mmtiddy Feb. 3 at 8:43 PM

$NRSN Look, I am not saying it is true, but I got the same response from ChatGPT 1 year ago, and look what has happened. I am not saying this company did this, but certain companies have paid for ”ghost advertising” on LLMs to promote their products, I find it wild that from all the biopharma pennystocks out there, the LLM treats $NRSN like a king when it comes to recommendations but fails to mention the core issues with this company Dishonest management, news being delayed for years, the amount of warrants on low prices, lack of actual articles about this company, something fishy is going on to me. This stock has killed me from the inside out, I was promised so many things from management and till now nothing has delivered, nor was I given a proper explanation of why they werent delivered Feel free to chat their Investor Relations for any answers, p.s they never respond

0 · Reply

PennyBLVD Feb. 3 at 6:55 PM

$NRSN PS… Now Following You🫵 👍

0 · Reply

PennyBLVD Feb. 3 at 6:54 PM

$NRSN WOW!!!👀 That’s Fantastic News!!! Thank you so much for this informative answer!!! 💯🙏

0 · Reply

Stekli27 Feb. 3 at 6:50 PM

$NRSN ALS (PrimeC): • Positive Phase 2b data • Acceptable safety profile • Phase 3 preparation pending funding / partner • This is the core value driver today Alzheimer’s (AD): • Separate program • Safety profile announced in December • Biomarker readout expected (Q1) • Still early-stage and not priced in What NRSN has: • Human clinical data • Clear unmet need in ALS • Active BD discussions What NRSN lacks: • Cash If financing or a partnership is secured, the risk profile changes completely and this is no longer a sub-$1 stock. It all depends on the deal structure, but upside could be very fast and very large (even 500–700%). CEO and team are currently traveling across the US, clearly trying to lock in funding or a partnership to start Phase 3 mid-year. This is a binary setup. And even without cash, analysts still keep Buy ratings with targets around ~$8. Some of us have been waiting here for more than a year already 😉

1 · Reply

PennyBLVD Feb. 3 at 5:32 PM

$NRSN can anyone else confirm this? I seriously can’t find anything! When I did my search on grok and google AI I was really hoping to find a stock that was maybe on the barcharts or something popular! I’ve never even heard of this company before today. If anyone else has some insight why grok and google would pick $NRSN it would be greatly appreciated🙏

0 · Reply

PennyBLVD Feb. 3 at 4:37 PM

$NRSN LFG🚀🚀🚀

0 · Reply

Speculator2 Feb. 3 at 3:49 PM

$NRSN New horizons?

0 · Reply

PennyBLVD Feb. 3 at 3:43 PM

$NRSN Just putting this out there! Hopefully correct🙏 https://x.com/grok/status/2018705342889185545?s=46

1 · Reply

knowthyself Feb. 3 at 3:16 PM

$NRSN looks good to me

0 · Reply

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

Jan 8, 2026, 8:45 AM EST - 26 days ago

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

Dec 22, 2025, 9:17 AM EST - 6 weeks ago

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

Dec 4, 2025, 7:30 AM EST - 2 months ago

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

Nov 24, 2025, 9:56 AM EST - 2 months ago

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

Nov 3, 2025, 9:15 AM EST - 3 months ago

NeuroSense to Host Investor Webinar on December 8, 2025

Oct 6, 2025, 9:00 AM EDT - 4 months ago

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

Sep 10, 2025, 2:30 PM EDT - 5 months ago

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Sep 4, 2025, 8:49 AM EDT - 5 months ago

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Aug 1, 2025, 9:00 AM EDT - 6 months ago

NeuroSense Provides Business Update and Progress for the First Half of 2025

Jul 22, 2025, 8:42 AM EDT - 7 months ago

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

May 12, 2025, 3:08 PM EDT - 9 months ago

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 7, 2025, 8:45 AM EDT - 9 months ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

Apr 24, 2025, 9:09 AM EDT - 10 months ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

Apr 9, 2025, 8:30 AM EDT - 10 months ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Apr 7, 2025, 5:14 PM EDT - 10 months ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

Apr 4, 2025, 9:10 AM EDT - 10 months ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Mar 17, 2025, 8:30 AM EDT - 11 months ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Jan 6, 2025, 9:00 AM EST - 1 year ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

Dec 23, 2024, 9:00 AM EST - 1 year ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Dec 18, 2024, 10:25 AM EST - 1 year ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

Dec 11, 2024, 9:25 AM EST - 1 year ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Dec 4, 2024, 8:30 AM EST - 1 year ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

Dec 2, 2024, 8:30 AM EST - 1 year ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

Nov 21, 2024, 9:20 AM EST - 1 year ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Oct 28, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Oct 24, 2024, 8:30 AM EDT - 1 year ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Oct 15, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Oct 9, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

Oct 7, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

Sep 24, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

Sep 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Aug 30, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Aug 7, 2024, 2:00 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

Aug 1, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

Jul 9, 2024, 9:27 AM EDT - 1 year ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Jul 2, 2024, 12:34 PM EDT - 1 year ago

This cheap biotech offers investors a play on ALS if trial data continues to impress

Jul 1, 2024, 8:00 AM EDT - 1 year ago

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

Jun 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Jun 21, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

May 20, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

May 14, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

May 7, 2024, 8:45 AM EDT - 1 year ago

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

May 2, 2024, 9:19 AM EDT - 1 year ago

NeuroSense Announces First Quarter 2024 Business Update

Apr 22, 2024, 8:30 AM EDT - 1 year ago

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

Apr 18, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

Apr 12, 2024, 8:30 AM EDT - 1 year ago

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

Apr 10, 2024, 7:16 PM EDT - 1 year ago

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

Apr 9, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

mmtiddy Feb. 3 at 8:52 PM

0 · Reply

mmtiddy Feb. 3 at 8:43 PM

0 · Reply

PennyBLVD Feb. 3 at 6:55 PM

$NRSN PS… Now Following You🫵 👍

0 · Reply

PennyBLVD Feb. 3 at 6:54 PM

$NRSN WOW!!!👀 That’s Fantastic News!!! Thank you so much for this informative answer!!! 💯🙏

0 · Reply

Stekli27 Feb. 3 at 6:50 PM

1 · Reply

PennyBLVD Feb. 3 at 5:32 PM

0 · Reply

PennyBLVD Feb. 3 at 4:37 PM

$NRSN LFG🚀🚀🚀

0 · Reply

Speculator2 Feb. 3 at 3:49 PM

$NRSN New horizons?

0 · Reply

PennyBLVD Feb. 3 at 3:43 PM

$NRSN Just putting this out there! Hopefully correct🙏 https://x.com/grok/status/2018705342889185545?s=46

1 · Reply

knowthyself Feb. 3 at 3:16 PM

$NRSN looks good to me

0 · Reply

lev57 Feb. 3 at 7:51 AM

$NRSN If you believe it's close, you'll be in for a surprise and you'll eat your hat. Amazing news. Can give a strong push to the company. To continue its activities. Good luck to the company, to the patients and to all of us.

0 · Reply

mmtiddy Feb. 3 at 6:37 AM

$NRSN Anything but finalizing a partnership deal huh Alon?

0 · Reply

lev57 Feb. 3 at 5:14 AM

$NRSN

0 · Reply

lev57 Feb. 3 at 5:13 AM

Great news! The Senate just passed a bill that increases funding for ALS research! We’re not done yet. The House needs to pass this bill. Let’s show them how important ALS research is. $NRSN

0 · Reply

lev57 Feb. 2 at 8:37 PM

$NRSN Regarding the CEO, he announced that he would be in Boston. Regarding the lady, I linked to a message that came out from someone close. I see you found her there. Link is solid.

2 · Reply

Stekli27 Feb. 2 at 5:22 PM

$NRSN Do you have some insiders? 😉 Sounds like you’re very well connected to the NRSN travel plans.😉

0 · Reply

Zoofar Feb. 2 at 4:51 PM

$NRSN Bot 2

0 · Reply

Zoofar Feb. 2 at 4:51 PM

$NRSN Bot 1

0 · Reply

Babilon1210 Feb. 2 at 4:20 PM

$NRSN What do you think will happen to the SP if they soon surprise us with finalizing the partnership with a big pharma like Biogen?

0 · Reply

lev57 Feb. 2 at 2:32 PM

$NRSN Every few minutes, a small portion of 100 is thrown in for buying and selling at about the low price in the range they set. And that's how they control where to move the paper price. Someone understands how someone sells at these levels and there is immediately a buyer who snatches it up. Together, we'll disrupt their plan

0 · Reply

mmtiddy Feb. 2 at 12:33 PM

$NRSN To add some context, they filed for a mixed shelf offering of $380 million back in May 15th 2023, stock price was around $5/share, they only touched this shelf offering at $23/share to raise $180 million in late 2025 Still a year and a half for them to see any results, was tied to the readout of their Phase 3 trials

0 · Reply

Zoofar Feb. 2 at 9:10 AM

$NRSN 13 months and counting… where is the MONEY 😂😂😂

0 · Reply

Market Cap	12.58M
Revenue (ttm)	0.00
Net Income (ttm)	-10.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	137,933
Avg Vol	336,824
Day's Range	N/A - N/A
Shares Out	13.67M
Stochastic %K	28%
Beta	1.62
Analysts	Sell
Price Target	$10.17